Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding Wages, Salaries and Other

Cytosorbents (CTSO) Long-Term Debt Repayments (2018 - 2024)

Cytosorbents filings provide 3 years of Long-Term Debt Repayments readings, the most recent being $4.4 million for Q2 2024.

On a quarterly basis, Long-Term Debt Repayments changed N/A to $4.4 million in Q2 2024 year-over-year; TTM through Dec 2024 was $5.0 million, a N/A change, with the full-year FY2024 number at $5.0 million, changed N/A from a year prior.
Long-Term Debt Repayments hit $4.4 million in Q2 2024 for Cytosorbents, up from $625000.0 in the prior quarter.
In the past five years, Long-Term Debt Repayments ranged from a high of $15.0 million in Q4 2020 to a low of $625000.0 in Q1 2024.